Erratum: Age-and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays (The Journal of Clinical Endocrinology & Metabolism (2014) 99:5 (1675-1686) DOI: 10.1210/jc.2013-3060);Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (igfbp-3) and the igf-i to igfbp-3 ratio measured by new automated chemiluminescence assays

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1675-1686

  Friedrich, Nele ^a   Wolthers, Ole D ^c   Arafat, Ayman M ^d,e   Emeny, Rebecca T ^f   Spranger, Joachim ^d   Roswall, Josefine ^g   Kratzsch, Jürgen ^h   Grabe, Hans J ^a,b   Hübener, Christoph ⁱ   Pfeiffer, Andreas F H ^d,e   Döring, Angela ^f   Bielohuby, Maximilian ⁱ   Dahlgren, Jovanna ^g   Frystyk, Jan ^j   Wallaschofski, Henri ^a   Bidlingmaier, Martin ⁱ  

^a Institute of Clinical Chemistry and Laboratory Medicine   (Germany)

^b HELIOS Hospital Stralsund   (Germany)

^c Children's Clinic Randers   (Denmark)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j AARHUS UNIVERSITY   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGE; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANADA; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EUROPE; FEMALE; HUMAN; IGF I TO IGFBP 3 RATIO; INTERMETHOD COMPARISON; LIFESPAN; MALE; MIDDLE AGED; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; REFERENCE VALUE; SCHOOL CHILD; SEX DIFFERENCE; UNITED STATES; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGING; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 84899925625     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/clinem/dgaa640     Document Type: Erratum

References (59)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
2. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003;13: 113-170.
3. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and-independent mechanisms. J Endocrinol. 2002;175:19-31.
4. Hussain MA Schmitz O Mengel A et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin se nsitivity in growth hormone-deficient humans J Clin Invest. 1994 94 1126-1133.
5. MuzumdarRH,MaX, Fishman S, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006;55:2788-2796.
6. Juul A, Main K, Blum WF, Lindholm J, RankeMB,Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1,-2 and-3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 1994;41:85-93.
7. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337-375.
8. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregr ession: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96:2912-2920.
9. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulinlike grow th factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94:1732-1739.
10. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis. 2007;28:2154-2159.
11. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009;30:417-437.
12. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormon e deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
13. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. Ame rican Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011;17(suppl 4):1-44.
14. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995;80:2534-2542.
15. Lofqvist C, Andersson E, Gelander L, et al. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab. 2005;90:1420-1427.
16. Alberti C, Chevenne D, Mercat I, et al.Serum concentrations of insulinlike growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem. 2011;57:1424-1435.
17. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555-559.
18. NCCLS. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2nd ed. NCCLS Document EP5-A2. Wayne, PA: NCCLS; 2004.
19. NCCLS. Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. NCCLS Document EP17-A. Wayne, PA: NCCLS; 2004.
20. Friedrich N, Schneider H, Dorr M, et al. All-cause mortality and serum insulin-like growth factor I in primary care patients. Growth Horm IGF Res. 2011;21:102-106.
21. Adeli K. Closing the gaps in pediatric reference intervals: The CALIPER initiative. Clin Biochem. 2011;44:480-482.
22. Lowel H, Doring A, Schneider A, Heier M, Thorand B, Meisinger C. The MONI CA Augsburg surveys-basis for prospective cohort studies. Gesundheitswesen. 2005;67(suppl 1):S13-S18.
23. Wichmann HE, Gieger C, Illig T. KORA-gen-resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen. 2005;67(suppl 1):S26-S30.
24. Cole TJ, Green PJ. Smoothing reference centile curves: The LMS method and penalized likelihood. Stat Med. 1992;11:1305-1319.
25. YeeTW.Quantile regression via vector generalized additive models. Stat Med. 2004;23:2295-2315.
26. Koenker R. Quantile regression New York: Cambridge University Press 2005.
27. Stone C, Koo CY. Additive splines in statistics. Washington, DC: American Statistical Association; 1985.
28. Hyun SE, Lee BC, Suh BK, et al. Refe rence values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents. Clin Biochem. 2012; 45:16-21.
29. Xu S, Gu X, Pan H, et al. Reference ranges for serum IGF-1 and IGFBP-3 levels in Chinese children during childhood and adolescence. Endocr J. 2010;57:221-228.
30. Elmlinger M W, Kuhnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 2004;42:654-664.
31. Soldin OP, Dahlin JR, Gresham EG, King J, Soldin SJ. IMMULITE 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem. 2008;41:937-942.
32. Kong AP, Wong GW, Choi KC, et al. Reference values for serum levels of insulin-like growth factor (IGF-1) and IGF-binding protein 3 (IGFBP-3) and their ratio in Chinese adolescents. Clin Biochem. 2007;40:1093-1099.
33. Bereket A, Turan S, Omar A, et al. Serum IGF-I and IGFB P-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res. 2006;65:96-105.
34. Friedrich N, Alte D, Volzke H, et al. Re ference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP).GrowthHormIGFRes. 2008; 18:228-237.
35. Friedrich N, Krebs A, Nauck M, Wal laschofski H. Age-and genderspecific reference ranges for serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations on the Immulite 2500: results of the Study of Health in Pomerania (SHIP). ClinChem Lab Med. 2010;48:115-120.
36. Greenall SA, Bentley JD, Pearce LA, et al. Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cance r. J Biol Chem. 2013;288:59-68.
37. Conover CA. Insulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab. 2008;294:E10-E14.
38. Yan X, Payet LD, Baxter RC, Firth SM. Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology. 2009; 150:4968-4976.
39. Cheng I, DeLellis Henderson K, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Met ab. 2007;92:3660-3666.
40. Nelson AE, Howe CJ, Nguyen TV, et al. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. J Clin Endocrinol Metab. 2006;91:4424-4432.
41. Berrigan D, Potischman N, Dodd KW, et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res. 2009;19:146-155.
42. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyl e correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): The multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2004;13: 1444-1451.
43. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50-to 80-year-old men and women. J Clin Endocrinol Metab. 1996;81:2534-2540.
44. Birzniece V, Meinhardt U, Gibney J, et al. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women. J Clin Endocrinol Metab. 2010;95:2099-2106.
45. Veldhuis JD, Erickson D, Iranmanesh A, Miles JM, Bowers CY. Sex-steroid control of the aging somatotropic axis. Endocrinol Metab Clin North Am. 2005:34:877-893, viii.
46. Empen K, Lorbeer R, V ölzke H, et al. Association of serum insulinlike growth factor I with endothelial function: results from the population-based Study of Health in Pomerania (SHIP). Eur J Endocrinol. 2010;163:617-623.
47. Glaser S Friedrich N Ewert R et al. Association between serum IGF-I and IGFBP-3 and lung function J Clin Endocrinol Metab. 2009 94(7)2452-2458.
48. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and ri sk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010;19:2298-2306.
49. Aleem E, Elshayeb A, Elhabachi N, Mansour AR, Gowily A, Hela A. Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. Oncol Lett. 2012;3:704-712.
50. KaplanRC,McGinnAP,PollakMN,et al. Associationof total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007;9 2:1319-1325.
51. Martin RM, Gunnell D, Whitley E, et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and pla que stability in an older adult population. J Clin Endocrinol Metab. 2008;93:1331-1338.
52. Volzke H, Nauck M, Rettig R, et al. Association between hepatic steatosis and serum IGF1 and IGFBP-3 le vels in a population-based sample. Eur J Endocrinol. 2009;161:705-713.
53. YamadaPM,LeeKW.Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009;296: C954-C976.
54. Chan SS, Twigg SM, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab. 2005;90:6588-6595.
55. Kim HS, Ali O, Shim M, et al. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res. 2007;61:159-164.
56. Silha JV, Gui Y, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab. 2002;283:E937-E945.
57. Bang P, Brismar K, Rosenfeld RG. Increased proteolysis of insulinlike growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 f ragment contained in the approximately 130-to 150-kDa ternary complex. J Clin Endocrinol Metab. 1994;78:1119-1127.
58. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci (Lond). 2009;116:507-512.
59. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-1 immunoassay conforming to recent international recommendations [published online February 27, 2014]. J Clin Endocrinol Metab. do i:10.1210/jc.2013-3059.